Infectious bronchitis coronavirus inhibits STAT1 signalling and requires accessory proteins for resistance to type I interferon

The innate immune response is the first line of defence against viruses and the type I interferon (IFN) is a critical component of this response. Similar to other viruses, the Gammacoronavirus infectious bronchitis virus (IBV) has evolved under evolutionary pressure to evade and counteract the IFN response to enable its survival. Previously, we reported that IBV induces a delayed activation of the IFN response. In the present work, we describe the resistance of IBV to IFN and the potential role of accessory proteins herein. We show that IBV is fairly resistant to the antiviral state induced by IFN and identify that the viral accessory proteins 3a is involved in resistance to IFN, as its absence renders IBV less resistant to IFN treatment. In addition to this, we find that independently of its accessory proteins, IBV inhibits IFN-mediated phosphorylation and translocation of STAT1. In summary, we show that IBV uses multiple strategies to counteract the IFN response.IMPORTANCE In the present study we show that infectious bronchitis virus (IBV) is resistant to IFN treatment and identify a role for the accessory proteins 3a in the resistance against the type I IFN response. We also demonstrated that, in a time-dependent manner, IBV effectively interferes with IFN signalling and that accessory proteins are dispensable for this activity. This study demonstrates that the Gammacoronavirus IBV, similar to its mammalian counterparts, has evolved multiple strategies to efficiently counteract the IFN response of its avian host, and identifies accessory protein 3a as multifaceted antagonist of the avian IFN system.

Trim content

® The Pirbright Institute 2024 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.